JP2006514111A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514111A5
JP2006514111A5 JP2005508468A JP2005508468A JP2006514111A5 JP 2006514111 A5 JP2006514111 A5 JP 2006514111A5 JP 2005508468 A JP2005508468 A JP 2005508468A JP 2005508468 A JP2005508468 A JP 2005508468A JP 2006514111 A5 JP2006514111 A5 JP 2006514111A5
Authority
JP
Japan
Prior art keywords
lactoferrin
terminal
oral preparation
composition
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2005508468A
Other languages
English (en)
Japanese (ja)
Other versions
JP4795021B2 (ja
JP2006514111A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/038621 external-priority patent/WO2004052281A2/en
Publication of JP2006514111A publication Critical patent/JP2006514111A/ja
Publication of JP2006514111A5 publication Critical patent/JP2006514111A5/ja
Application granted granted Critical
Publication of JP4795021B2 publication Critical patent/JP4795021B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2005508468A 2002-12-06 2003-12-05 敗血症治療における経口用ラクトフェリン Expired - Fee Related JP4795021B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43139302P 2002-12-06 2002-12-06
US60/431,393 2002-12-06
US49832703P 2003-08-27 2003-08-27
US60/498,327 2003-08-27
PCT/US2003/038621 WO2004052281A2 (en) 2002-12-06 2003-12-05 Oral lactoferrin in the treatment of sepsis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010265361A Division JP2011068666A (ja) 2002-12-06 2010-11-29 敗血症治療における経口用ラクトフェリン

Publications (3)

Publication Number Publication Date
JP2006514111A JP2006514111A (ja) 2006-04-27
JP2006514111A5 true JP2006514111A5 (cg-RX-API-DMAC7.html) 2006-11-24
JP4795021B2 JP4795021B2 (ja) 2011-10-19

Family

ID=32511559

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2005508468A Expired - Fee Related JP4795021B2 (ja) 2002-12-06 2003-12-05 敗血症治療における経口用ラクトフェリン
JP2010265361A Pending JP2011068666A (ja) 2002-12-06 2010-11-29 敗血症治療における経口用ラクトフェリン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010265361A Pending JP2011068666A (ja) 2002-12-06 2010-11-29 敗血症治療における経口用ラクトフェリン

Country Status (6)

Country Link
US (2) US20040152624A1 (cg-RX-API-DMAC7.html)
EP (1) EP1581243A4 (cg-RX-API-DMAC7.html)
JP (2) JP4795021B2 (cg-RX-API-DMAC7.html)
AU (2) AU2003298906A1 (cg-RX-API-DMAC7.html)
CA (1) CA2508912A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004052281A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
DK2298338T3 (da) 2002-09-16 2012-09-24 Agennix Inc Lactoferrin-sammensætninger og fremgangsmåder til behandling af hudsår
JP4795021B2 (ja) * 2002-12-06 2011-10-19 エイジェニックス インコーポレイテッド 敗血症治療における経口用ラクトフェリン
US7592306B2 (en) * 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
AU2004289170B2 (en) * 2003-06-06 2009-12-17 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
ITMI20052351A1 (it) * 2005-12-09 2007-06-10 Microbo Srl Nuovo uso farmaceutico delle transferrine e composizioni farmaceutiche derivate
UY30227A1 (es) * 2006-03-20 2007-10-31 Glanbia Nutritionals Ireland Ltd Composiciones y métodos para aumentar la vasodilatacion
JP5087297B2 (ja) * 2007-03-05 2012-12-05 森永乳業株式会社 インターロイキン−11産生促進剤
ITRM20080163A1 (it) * 2008-03-26 2009-09-27 Maurizio Acri Uso della lattoferrina per la prevenzione delle sepsi neonatali in neonati prematuri
EP2416800A1 (en) 2010-02-25 2012-02-15 Agennix AG Oral lactoferrin in the treatment of severe sepsis
CN101829075B (zh) * 2010-04-27 2011-07-20 中国人民解放军第三军医大学第一附属医院 苦柯胺a和苦柯胺b的用途
CA2911483C (en) * 2013-04-09 2022-10-04 The University Of Tokyo Inhibitor of extracellular trap formation in leukocytes
EP4142773A4 (en) * 2020-04-29 2023-11-01 The Regents Of The University Of Michigan INHIBITION OF SARS-COV-2 VIRUS ENTRY BY ADMINISTRATION OF LACTOFERRIN AND USES THEREOF
WO2022145536A1 (ko) * 2020-12-30 2022-07-07 경상대학교병원 급성 호흡 곤란 증후군 환자의 예후 예측을 위한 정보제공방법
WO2023178060A1 (en) * 2022-03-14 2023-09-21 The Children's Mercy Hospital Prophylaxis of neonatal escherichia coli sepsis

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2710997C3 (de) * 1977-03-14 1980-08-14 Dr. Karl Thomae Gmbh, 7950 Biberach 4-Alkoxy carbonylamino-phenyläthanolamine, deren Herstellung und deren Verwendung als Arzneimittel
US4977137B1 (en) * 1987-06-03 1994-06-28 Baylor College Medicine Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
US6100054A (en) * 1989-05-05 2000-08-08 Baylor College Of Medicine Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms
US5849881A (en) * 1989-05-05 1998-12-15 Baylor College Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
US5571697A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US5571691A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5766939A (en) * 1989-05-05 1998-06-16 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
IL94183A (en) * 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US5198419A (en) * 1989-12-08 1993-03-30 Immuno Japan Inc. Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria
US6066469A (en) * 1990-03-08 2000-05-23 Ferro Dynamics, Inc. Cloning, expression, and uses of human lactoferrin
US5240909B1 (en) * 1990-03-14 1998-01-20 Dietrich Nitsche Use of lactoferrin for treatment of toxic effects of endotoxins
DK0579830T3 (da) * 1990-11-13 1997-08-18 Santen Pharmaceutical Co Ltd Terapeutisk middel til hornhindebeskadigelse
US5564109A (en) * 1991-09-13 1996-10-08 Eastman Kodak Company Remote user interface for prioritizing and selecting from a plurality of document production peripheral devices
DK0559425T3 (da) * 1992-03-02 1999-08-30 Japan Immuno Inc Anvendelse af proteiner tilhørende transferrin/lactoferrinfamilien til stimulering af immunsystemet
JPH06145068A (ja) * 1992-04-02 1994-05-24 Imuno Japan:Kk 生体防御能賦活剤・感染症治療剤・生体防御能賦活性食品
ZA932568B (en) * 1992-04-24 1993-11-12 Baylor College Midecine A Non Production of recombinant human lactoferrin
DK0624376T3 (da) * 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
JP3506274B2 (ja) * 1994-09-01 2004-03-15 雪印乳業株式会社 新規ペプチドおよび免疫賦活剤
JPH08165248A (ja) * 1994-12-15 1996-06-25 Nobuo Kuriiwa エンドトキシンによる炎症の抑止剤
US20020016289A1 (en) * 1995-06-01 2002-02-07 Orla M. Conneely Methods for treatment and prevention of helicobacter pylori infection using lactoferrin
US6025326A (en) * 1995-07-07 2000-02-15 Intrabiotics Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of oral mucositis
US5834424A (en) * 1995-07-12 1998-11-10 Gambit International Limited Use of lactoferrin for therapy of acute of chronic infectious diseases by the intracellular gram-positive pathogens streptococcus pyogenes and staphylococcus aureus
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof
JP2002515893A (ja) * 1997-02-03 2002-05-28 ファーミング インテレクチュアル プロパティ ビーブイ ヒトラクトフェリンおよびその改変体の有用な特性
ATE297755T1 (de) * 1997-04-10 2005-07-15 Agennix Inc Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
US5981830A (en) * 1997-05-30 1999-11-09 Schering Aktiengesellschaft Knockout mice and their progeny with a disrupted hepsin gene
US6096731A (en) * 1998-06-24 2000-08-01 Institute For Drug Research, Inc. Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US20030203839A1 (en) * 1999-10-29 2003-10-30 Kruzel Marian L. Immune enhancing composition containing lactoferrin
US6613741B2 (en) * 1999-10-29 2003-09-02 Ferro Dynamics, Inc. Method for treating aseptic SIRS in humans and other animals
AU782539B2 (en) * 2000-01-14 2005-08-04 Meiji Dairies Corporation Antigen-specific IgE antibody production inhibitors
JP4672163B2 (ja) * 2000-03-24 2011-04-20 明治乳業株式会社 グラム陰性菌のリピドaに対する特異的抗体産生を誘導する組成物。
US7087578B2 (en) * 2000-05-24 2006-08-08 Eli Lilly And Company Formulations and methods for treating hypercoagulable states
JP4683740B2 (ja) * 2001-02-15 2011-05-18 明治乳業株式会社 炎症に伴う症状の軽減剤
US20030096736A1 (en) * 2001-05-09 2003-05-22 Kruzel Marian L. Lactoferrin for age related disorders in humans
EP2286827A1 (en) * 2002-05-10 2011-02-23 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
AU2003233583A1 (en) * 2002-05-24 2003-12-12 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
DK2298338T3 (da) * 2002-09-16 2012-09-24 Agennix Inc Lactoferrin-sammensætninger og fremgangsmåder til behandling af hudsår
AU2003291206A1 (en) * 2002-12-04 2004-06-23 Agennix Incorporated Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease
JP4795021B2 (ja) * 2002-12-06 2011-10-19 エイジェニックス インコーポレイテッド 敗血症治療における経口用ラクトフェリン
US7592306B2 (en) * 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
US7323443B2 (en) * 2002-12-12 2008-01-29 Agennix Inc. Lactoferrin in the reduction of pain
WO2004103285A2 (en) * 2003-05-14 2004-12-02 Agennix Incorporated Lactoferrin in the treatment of diabetes mellitus
AU2004289170B2 (en) * 2003-06-06 2009-12-17 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects

Similar Documents

Publication Publication Date Title
ES2358645T3 (es) Composiciones de lactoferrina y métodos de tratamiento de la úlcera diabética.
JP2014521684A5 (cg-RX-API-DMAC7.html)
CN102292346B (zh) 肥胖的治疗
JP2006507270A5 (cg-RX-API-DMAC7.html)
ES2316567T3 (es) Adeponectina para la regeneracion hepatica.
WO2001060381B1 (en) Nucleoside analogs with carboxamidine-modified bicyclic base
RU2008136208A (ru) Композиции для эффектора плотных контактов
ES2365648T3 (es) Administración oral de una calcitonina.
JP2009507838A5 (cg-RX-API-DMAC7.html)
AP2002002410A0 (en) Hydrodynamically Balancing Oral Drug Delivery System
JP2011068666A (ja) 敗血症治療における経口用ラクトフェリン
JP2000503652A (ja) 合成il―10類似体
RU2009142937A (ru) Тапентадол для лечения в связи с остеоартрозом
ES2640979T3 (es) Formulaciones de células viables para administración oral
KR20100091991A (ko) 면역 관련 질병을 예방 및 치료하기 위한 조성물 및 방법
JP2007502303A5 (cg-RX-API-DMAC7.html)
WO2008020096A1 (es) Composición farmacéutica con promotores de absorción
ES2547379T3 (es) Utilización de calcitonina para el tratamiento de la AR
US12146005B2 (en) Compositions and methods for treatment of fungal infections
WO2005018542A2 (en) Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
RU2295972C2 (ru) Композиции на основе белков матрикса зубной эмали для модуляции иммунного ответа
US20250222082A1 (en) Protein and peptide vaccines targeting methanogens
JP2818834B2 (ja) IL−1α安定化医薬製剤
JP2008514651A (ja) 上皮増殖因子(egf)を含んで成る再水和組成物
SE8701077D0 (sv) Pharmaceutical composition